Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stump

Showing results (921-930 of 1,095) with videos related to

Pageof 110
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 19, 2015
AIMing towards improved antitumor efficacyMatthew J Weaver, Alison K Kearns, Sascha Stump, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|December 22, 2009
Juvenile animal toxicity study designs to support pediatric drug developmentGregg D Cappon, Graham P Bailey, Jochen Buschmann, et al.
Circulation|May 1, 1988
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarctionE J Topol, R M Califf, B S George, et al.
Journal of Clinical Pharmacology|April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairmentKimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.
Journal of Cardiovascular Pharmacology|January 9, 2009
Hemodynamic and cardiac neurotransmitter-releasing effects in conscious dogs of attention- and wake-promoting agents: a comparison of d-amphetamine, atomoxetine, modafinil, and a novel quinazolinone H3 inverse agonistJoseph Lynch, Christopher Regan, Gary Stump, et al.
Circulation|February 1, 1989
A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarctionE J Topol, B S George, D J Kereiakes, et al.
Preventive Medicine Reports|December 19, 2022
Factors associated with the accurate self-report of cancer screening behaviors among women living in the rural Midwest region of the United StatesMira L Katz, Timothy E Stump, Patrick O Monahan, et al.
The Journal of Experimental Medicine|January 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancerLestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
Nature Genetics|February 14, 1998
GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrierG Seidner, M G Alvarez, J I Yeh, et al.
Thrombosis and Haemostasis|March 4, 1991
Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarctionD C Sane, D C Stump, E J Topol, et al.
Pageof 110

Showing results (921-930 of 1,095) with videos related to

Sort By:
Pageof 110
Bioorganic & Medicinal Chemistry Letters|March 19, 2015
AIMing towards improved antitumor efficacyMatthew J Weaver, Alison K Kearns, Sascha Stump, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|December 22, 2009
Juvenile animal toxicity study designs to support pediatric drug developmentGregg D Cappon, Graham P Bailey, Jochen Buschmann, et al.
Circulation|May 1, 1988
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarctionE J Topol, R M Califf, B S George, et al.
Journal of Clinical Pharmacology|April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairmentKimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.
Journal of Cardiovascular Pharmacology|January 9, 2009
Hemodynamic and cardiac neurotransmitter-releasing effects in conscious dogs of attention- and wake-promoting agents: a comparison of d-amphetamine, atomoxetine, modafinil, and a novel quinazolinone H3 inverse agonistJoseph Lynch, Christopher Regan, Gary Stump, et al.
Circulation|February 1, 1989
A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarctionE J Topol, B S George, D J Kereiakes, et al.
Preventive Medicine Reports|December 19, 2022
Factors associated with the accurate self-report of cancer screening behaviors among women living in the rural Midwest region of the United StatesMira L Katz, Timothy E Stump, Patrick O Monahan, et al.
The Journal of Experimental Medicine|January 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancerLestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
Nature Genetics|February 14, 1998
GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrierG Seidner, M G Alvarez, J I Yeh, et al.
Thrombosis and Haemostasis|March 4, 1991
Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarctionD C Sane, D C Stump, E J Topol, et al.
Pageof 110